Abstract
Global regulatory initiatives have increased the number of pediatric psychopharmacology trials. Challenges in ensuring valid and reliable data in such trials include developmental limitations in symptom description, the need to combine and calibrate information from varied sources, including patients and parents/caregivers, and a dearth of pediatric-specific scales. Pediatric schizophrenia trials, with few exceptions, have used for primary efficacy assessment the (adult) Positive and Negative Syndrome Scale (PANSS), a complex and lengthy 30-item measure that has been shown to pose ratings challenges even in the adult populations for whom it was designed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
